TITLE

High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome: COMMENTARY

AUTHOR(S)
Eikelboom, John W.
PUB. DATE
March 2004
SOURCE
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p38
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article comments on a study conducted to compare the effectiveness of high-intensity and moderate-intensity of warfarin for preventing recurrent thrombosis. Patients with antiphospholipid antibodies who develop thrombosis are generally recommended to continue warfarin therapy indefinitely. The study is the first randomized trial to determine whether high-intensity warfarin is more effective than moderate-intensity warfarin for preventing recurrent thrombosis in patients with antiphospholipid antibodies. Unfortunately, the study lacked the power to reliably answer the question because the observed incidence of recurrent thrombosis was much lower than expected.
ACCESSION #
12597125

 

Related Articles

  • The Lesser Known Side-Effect of Warfarin: Warfarin-Induced Venous Limb Gangrene. Hau Sheng, Garrett; Aronowitz, Paul // Mayo Clinic Proceedings;May2014, Vol. 89 Issue 5, pe47 

    The article describes the case of an 84 year old woman presented with severe bilateral necrotic changes over her legs and arms. She had been on warfarin therapy 3 months earlier after a diagnosis of antiphospholipid antibody syndrome. Skin biopsy specimens showed necrosis secondary to vascular...

  • High- and moderate-intensity warfarin regimens did not differ for preventing thrombosis in the antiphospholipid antibody syndrome.  // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p38 

    The article analyses if high-intensity warfarin more effective than moderate-intensity warfarin for preventing recurrent thrombosis in patients with previous arterial or venous thrombosis and the antiphospholipid antibody syndrome. 114 patients who had an objectively confirmed arterial or venous...

  • An Update on Pathogenic Mechanisms Mediated by Antiphospholipid Antibodies. Doan, Ellis; Dang, Neha; Pierangeli, Silvia S. // International Journal of Advances in Rheumatology;2010, Vol. 8 Issue 1, p16 

    Antiphospholipid (aPL) antibodies are associated with thrombosis and are a risk factor for recurrent pregnancy loss and obstetric complications in patients with the antiphospholipid syndrome (APS). It is generally accepted that the major autoantigen for aPL antibodies is β2glycoprotein I...

  • Idiopathic venous thromboembolism and thrombophilia. C., Sinescu; M., Hostiuc; D., Bartos // Journal of Medicine & Life;Jan-Mar2011, Vol. 4 Issue 1, p57 

    During the past decade idiopathic venous thromboembolism has become a separate entity, a chronic illness which has required prolonged anticoagulation and other prevention strategies to avoid recurrences. This article reviews recent developments regarding unprovoked venous thromboembolism and its...

  • PLASMA HOMOCYSTEINE AND VENOUS THROMBOTIC DISEASE IN SLE PATIENTS.  // Lupus;Jan2001 Supplement 1, Vol. 10, pS27 

    An abstract of the article "Plasma Homocysteine and Venous Thrombotic Disease in SLE Patients" is presented. It evaluates the relationship between plasma total homocysteine (tHey) concentrations and the risk of venous thrombotic disease in systemic lupus erythematosus (SLE) patients. The study...

  • HIV Infection and Antiphospholipid Antibody: Literature Review and Link to the Antiphospholipid Syndrome. Hassoun, Ali; Al-Kadhimi, Zaid; Cervia, Joseph // AIDS Patient Care & STDs;Jun2004, Vol. 18 Issue 6, p333 

    There is a high incidence of antiphospholipid antibodies, detected by assays for anticardiolipin or lupus-like anticoagulant, in HIV disease. However, a link to the antiphospholipid syndrome, with clinical thrombosis, is tenuous. We report a case of a 25-year-old man with undetermined risk...

  • Extended-Release Formulations of Antiepileptic Drugs: Rationale and Comparative Value. Perucca, Emilio // Epilepsy Currents;Nov/Dec2009, Vol. 9 Issue 6, p153 

    Extended-release products are designed to prolong the absorption of drugs with short half-lives, thereby allowing longer dosing intervals while minimizing fluctuations in serum drug levels. The relationship between serum drug concentration and clinical effects of antiepileptic drugs (AEDs) can...

  • Intracardiac multiple thrombus formation as a rare manifestation of primary antiphospholipid antibody syndrome: a case report. Uyar, I Sami; Uyar, B; Erdogan, I; Sivrikoz, O Nermin; Kobak, S; Alayunt, E Alp // Lupus;Jun2014, Vol. 23 Issue 7, p721 

    A letter to the editor is presented commenting on intracardiac multiple thrombus formation as a rare manifestation of primary antiphospholipid antibody syndrome.

  • Ximelagatran was noninferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation: COMMENTARY. van Walraven, Carl // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p39 

    The article comments on the study conducted to examine the efficacy of ximelagatran over warfarin in patients with atrial fibrillation (AF) at moderate to high risk for thromboembolic outcomes. From a practical standpoint, ximelagatran is an easier drug to use than warfarin because it can be...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics